MedPlus Health Services Limited MEDPLUS NSEPHARMA

Healthcare · Pharmaceutical Retailers · India

https://www.medplusindia.com

MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness products, such as prescription medicines, over-the-counter drugs, vitamins, medical devices, and diagnostic test kits; and fast-moving consumer goods (FMCG), including personal and home care products like toiletries, baby care items, soaps, detergents, and sanitizers. The company also engages in wholesale cash and carry; provision of diagnostic, pathological, and laboratory testing services, as well as contract manufacturing of private-label pharmaceuticals, wellness products, and FMCG goods; and operates diagnostic centres. It distributes its products through retail and online channels. The company was incorporated in 2006 and is based in Hyderabad, India.

Market & Price

Market Cap

₹10,750.08 Cr

Current Price

₹895.20

High / Low (52W)

₹972.00 / ₹741.80

Beta

0.43

Valuation

Stock P/E

49.03

Industry PE

37.60

Forward P/E

35.05

PEG Ratio

Book Value

₹164.55

Price to Book

5.44

P/S

1.56

EV/EBITDA

28.64

Dividend Yield

Profitability & Returns

ROCE

12.20%

ROE

11.82%

ROA

5.56%

Profit Margin

3.19%

Op Margin

5.00%

EPS (Latest Qtr)

₹5.33

EPS (TTM)

₹18.26

Balance Sheet & Liquidity

Debt/Equity

0.72

Quick Ratio

0.93

Current Ratio

3.00

Debt

₹1,424.38 Cr

Total Assets

₹3,932.53 Cr

Current Assets

₹2,068.65 Cr

Working Capital

₹1,379.36 Cr

Ownership

Promoter Holding

41.70%

Chg in Prom Hold

FII / Inst Holding

38.03%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹11,556.99 Cr

Total Revenue (TTM)

₹6,892.47 Cr

EBITDA

₹403.47 Cr

Free Cash Flow

₹271.58 Cr

Operating Cash Flow

₹495.58 Cr

Shares Outstanding

₹12.01 Cr

Gross Margin

26.23%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

15.03%

Profit 5Y

64.04%

Revenue (YoY)

23.50%

Earnings (YoY)

24.10%

PROS

Compounding revenue at 15.0% over 5 years.
Profit CAGR of 64.0% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	MEDPLUS MedPlus Health Services Limited NSEPHARMA	895.20	49.03	₹10,750.08 Cr	-	12.20%	11.82%	15.03%	64.04%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Dec 2024	Mar 2025	Jun 2025	Dec 2025	Mar 2026
Revenue	1,561.45 Cr	1,509.61 Cr	1,542.63 Cr	1,806.12 Cr	1,864.38 Cr
Cost of Revenue	1,170.58 Cr	1,108.64 Cr	1,139.74 Cr	1,333.68 Cr	1,370.94 Cr
Gross Profit	390.86 Cr	400.97 Cr	402.90 Cr	472.44 Cr	493.44 Cr
Operating Expenses	320.81 Cr	328.81 Cr	337.79 Cr	386.57 Cr	400.21 Cr
Operating Income	70.06 Cr	72.17 Cr	65.11 Cr	85.88 Cr	93.23 Cr
EBITDA	145.04 Cr	152.17 Cr	145.75 Cr	176.86 Cr	189.77 Cr
Interest Expense	25.97 Cr	26.84 Cr	27.36 Cr	30.83 Cr	33.48 Cr
Pretax Income	56.60 Cr	61.12 Cr	52.77 Cr	73.29 Cr	80.34 Cr
Tax Provision	10.73 Cr	9.80 Cr	10.42 Cr	15.50 Cr	16.37 Cr
Net Income	45.89 Cr	51.34 Cr	42.36 Cr	57.81 Cr	63.98 Cr
Diluted EPS	3.82	4.30	3.53	4.81	5.33

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	4,528.68 Cr	5,573.54 Cr	6,136.05 Cr	6,892.47 Cr
Cost of Revenue	-	3,557.69 Cr	4,391.63 Cr	4,640.66 Cr	5,084.61 Cr
Gross Profit	-	970.99 Cr	1,181.91 Cr	1,495.39 Cr	1,807.86 Cr
Operating Expenses	-	883.66 Cr	1,050.38 Cr	1,258.13 Cr	1,483.36 Cr
Operating Income	-	87.33 Cr	131.53 Cr	237.26 Cr	324.50 Cr
EBITDA	-	312.23 Cr	394.09 Cr	535.72 Cr	678.69 Cr
Interest Expense	-	83.03 Cr	96.43 Cr	102.59 Cr	120.49 Cr
Pretax Income	-	47.16 Cr	73.44 Cr	183.29 Cr	275.33 Cr
Tax Provision	-	-2.94 Cr	7.87 Cr	33.06 Cr	55.72 Cr
Net Income	-	49.76 Cr	65.47 Cr	150.32 Cr	219.65 Cr
Diluted EPS	-	4.17	5.45	12.52	18.29

Compounded Sales Growth

5 Years:	15.03%
1 Year:	23.50%

Compounded Profit Growth

5 Years:	64.04%
1 Year:	24.10%

Stock Price Performance

1 Year:	-7.90%
6 Months:	+16.65%
3 Months:	+7.18%
1 Month:	+1.66%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	2,796.72 Cr	3,004.80 Cr	3,360.09 Cr	3,932.53 Cr
Current Assets	-	1,480.72 Cr	1,567.55 Cr	1,843.52 Cr	2,068.65 Cr
Cash & Equivalents	-	228.38 Cr	91.21 Cr	86.05 Cr	198.41 Cr
Inventory	-	1,144.09 Cr	1,340.23 Cr	1,345.10 Cr	1,381.69 Cr
Receivables	-	6.68 Cr	12.25 Cr	7.96 Cr	26.96 Cr
Total Liabilities	-	1,306.22 Cr	1,427.44 Cr	1,620.20 Cr	1,957.87 Cr
Current Liabilities	-	476.58 Cr	525.93 Cr	576.59 Cr	689.29 Cr
Long Term Debt	0	-	-	-	-
Total Debt	-	899.92 Cr	1,009.57 Cr	1,119.80 Cr	1,424.38 Cr
Total Equity	-	1,491.18 Cr	1,577.93 Cr	1,740.56 Cr	1,975.36 Cr
Shares Outstanding	-	11.93 Cr	11.95 Cr	11.97 Cr	12.01 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	90.41 Cr	143.74 Cr	540.43 Cr	495.58 Cr
Investing Cash Flow	-	429.44 Cr	-82.80 Cr	-317.61 Cr	-127.72 Cr
Financing Cash Flow	-	-170.25 Cr	-198.10 Cr	-227.98 Cr	-255.50 Cr
Capital Expenditure	-	-169.00 Cr	-84.40 Cr	-59.45 Cr	-123.03 Cr
Free Cash Flow	-	-78.60 Cr	59.34 Cr	480.98 Cr	372.55 Cr
Net Change in Cash	-	349.60 Cr	-137.17 Cr	-5.16 Cr	112.36 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	21.4%	21.2%	24.4%	26.2%
Operating Margin %	-	1.9%	2.4%	3.9%	4.7%
Net Margin %	-	1.1%	1.2%	2.4%	3.2%
ROE %	-	3.3%	4.1%	8.6%	11.1%
ROCE %	-	3.8%	5.3%	8.5%	10.0%

Shareholding Pattern

Insiders

41.70%

Institutions

38.03%

Public Float

65.23%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MEDPLUS

No recent headlines available.

MEDPLUS · Healthcare